PVP VENTURES LTD.

PVP Ventures Ltd has announced an amendment to its Non-Convertible Debenture (NCD) transaction documents, deferring the principal repayment date from June 2026 to June 2027. This change has been executed through an Amendment Agreement to the Debenture Trust Deed, dated April 7, 2025, with the amendment agreement signed on June 25, 2026. The company has submitted the Amendment to the Debenture Trust Deed and an Addendum to the Key Information Document, along with approval from the National Stock Exchange of India Limited, for regulatory compliance and dissemination. The deferment was made pursuant to requisite approvals.

PVP Ventures Ltd has announced the closure of its trading window for all designated persons, their immediate relatives, and other insiders. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut from July 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The specific date for the board meeting to approve these results will be communicated later.

PVP Ventures Ltd has announced the record date for the interest payment on its Non-Convertible Debentures (NCDs). The record date is fixed as Tuesday, June 23, 2026, for two specific NCD series (ISINs INE362A07054 and INE362A07047). Interest will be paid on Wednesday, June 24, 2026, to eligible debenture holders registered as of the record date. This announcement complies with SEBI regulations.

PVP Ventures Ltd has filed a corrigendum to its Key Information Document (KID) for listed Non-Convertible Debentures (NCDs) dated March 28, 2025. The corrigendum incorporates the repayment schedule and clarifies certain terms. Key corrections include updating the coupon payment frequency from annual to quarterly for the 18% per annum NCDs and rectifying a typographical error in the issue size from 1,500 to 15,000 debentures. The NCDs have a face value of ₹1,00,000 each, a total issue size of up to ₹150 Crores, a 48-month tenor, and a 1% annual redemption premium.

PVP Ventures Ltd's board approved the audited standalone and consolidated financial statements for the quarter and financial year ended March 31, 2026. They also approved a scheme of amalgamation of PVP Corporate Parks Private Limited with the company, subject to approvals. The board approved the reconstitution of various committees and reviewed the security cover certificate for the quarter and financial year ended March 31, 2026.

PVP Ventures Ltd's board approved the audited standalone and consolidated financial statements for the quarter and financial year ended March 31, 2026. They also approved the proposed scheme of amalgamation of PVP Corporate Parks Private Limited with the company, subject to approvals. The board approved the reconstitution of various committees. For FY26, the company reported total income of ₹2,049.26 Lakhs and net profit of ₹90.99 Lakhs.

PVP Ventures Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the Audited Standalone & Consolidated Financial Results for the quarter and year ended March 31, 2026. The trading window has been closed from April 1, 2026, and will remain closed until 48 hours after the declaration of the results.

PVP Ventures Ltd issued a corrigendum regarding the appointment of Dr. Neeraja Nagarajan as Additional Director and Chief Operating Officer (COO). While the initial announcement stated the appointment would be effective from May 15, 2026, the company clarified that Dr. Nagarajan will assume office from July 1, 2026. All other details from the original board meeting outcome remain unchanged.

PVP Ventures Ltd's board approved changing the company name to "Evervie Health Limited," pending shareholder approval. They appointed Saloni Khandelwal, Ellen Feehan, and Srivatsan Kalyanasundaram as Non-Executive Independent Directors, also subject to shareholder approval. Dr. Neeraja Nagarajan was appointed as Additional Director and COO, and Mr. Raghu Chaitanya as CFO, effective June 1, 2026. The board also approved forming an International Holding Company for healthcare expansion in the Middle East and UK.

PVP Ventures Ltd's board approved changing the company name to Evervie Health Limited, subject to shareholder approval. The board also approved the appointment of Ms. Saloni Khandelwal, Dr. Ellen Feehan, and Mr. Srivatsan Kalyanasundaram as Non-Executive Independent Directors, effective May 15, 2026, also subject to shareholder approval. Additionally, Dr. Neeraja Nagarajan was appointed as an Additional Director and COO, and Mr. Raghu Chaitanya as CFO, effective June 1, 2026. The board also approved forming an International Holding Company for healthcare expansion.